-
Mashup Score: 2Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer - Full Text View - ClinicalTrials.gov - 10 month(s) ago
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer – Full Text View.
Source: classic.clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Dr. Antonio Wolff and Dr. Kim Allison discuss the latest ASCO-CAP guideline update on HER2 testing in breast cancer. This guideline update affirms previous recommendations, and provides commentary based on data from the DESTINY-Breast04 trial. Dr. Wolff and Dr. Allison review the questions from the oncology and pathology community raised by these results, and provide commentary on patients with…
Source: sites.libsyn.comCategories: Latest Headlines, Oncologists1Tweet-
HER2 Testing: ASCO-CAP Guideline Update. Imp and helpful commentary @awolff - at that low level, IHC is really sensitive to subtle analytic factors. A slide sitting unstained for a week or so might change a 1+ to a 0 result. #bcsm https://t.co/925VfAKOQ3
-
-
Mashup Score: 2
EDMONTON, Alberta, March 27, 2023 (GLOBE NEWSWIRE) — Translational Research In Oncology (TRIO) today announced positive topline results from NATALEE…
Source: GlobeNewswire News RoomCategories: Hem/Oncs, Latest HeadlinesTweet-
Positive results from Natalee trial evaluating ribociclib, CDK 4/6i with ET vs ET as adjuvant therapy for early HR+ breast cancer. Different from MONARCH-E/abemaciclib: 3 year ribo duration & inclusion of stage II-III disease. #bcsm @TRIOncology https://t.co/49h4Ay1PqB
-
-
Mashup Score: 2ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease - 1 year(s) ago
Triple-negative breast cancer (TNBC) patients with residual disease (RD) after neoadjuvant systemic therapy (NAST) are at high risk for recurrence. Biomarkers to risk-stratify patients with RD could help individualize adjuvant therapy and inform future adjuvant therapy trials. We aim to investigate the impact of circulating tumor DNA (ctDNA) status and residual cancer burden (RCB) class on…
Source: www.nature.comCategories: Latest Headlines, Oncologists1Tweet-
RT @MCristofanill: ctDNA complementary prognostic value in TNBC suggests consideration as surrogate endpoint. https://t.co/JkpK4Zremp @isli…
-
-
Mashup Score: 0Untying the Gordian Knot Evolving: Exploring Novel Treatments and Future Prospects in TNBC | Twitter Chat Registration - 2 year(s) ago
Triple Negative Breast Cancer Twitter Chat w/ Dr. Aditya Bardia & Dr. Rebecca Shatsky Event Timing: Tuesday, October 18, 2022 @ 8p ET/ 7p CT/ 5p PT Location: Twitter (@BonumCE) REGISTER HERE to RECEIVE EVENT REMINDERS & a CALENDAR HOLD
Source: Google DocsCategories: Hem/Oncs, Latest HeadlinesTweet-
TNBC: Many questions. #OncTwitter - Will discuss treatments for #TNBC w @Dr_RShatsky #bcsmchat Tue Oct 18 @ 8p ET/ 7p CT/ 5p PT Register for alerts https://t.co/qwHaXTDVX2
-
-
Mashup Score: 4Selective ER degraders in breast cancer: mixed results - 2 year(s) ago
There is a need to better investigate the mechanisms of action, define the optimal timing of administration and identify predictive biomarke
Source: Daily ReporterCategories: Latest Headlines, Oncologists1Tweet-
RT @myESMO: Mixed results from the use of SERMs and SERDs in advanced #BreastCancer 👉https://t.co/ozELdSC6Qb #ESMO22 @CarmenCriscit @dradit…
-
-
Mashup Score: 3
Results consistent with previous trials, reinforcing benefit of AstraZeneca and Daiichi Sankyo’s Enhertu in previously treated patients Positive high-level results from the DESTINY-Breast02 Phase III trial of Enhertu (trastuzumab deruxtecan) versus physician’s choice of treatment showed the trial met the primary endpoint, demonstrating a statistically significant and clinically meaningful…
Source: www.astrazeneca.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Enhertu significantly delayed disease progression in DESTINY-Breast02 Phase III trial vs. physician’s choice of treatment in patients with HER2-positive metastatic breast cancer https://t.co/51U45lDAKq
-
Back to back positive news on overall survival improvement with ADCs: T-DxD (HER2 ADC) for HER2+ MBC and Sacituzumab Govitecan (trop2 ADC) for HR+ MBC. Wonderful news for patients and the field. A) T-DxD: https://t.co/96CcuPG4KL B) SG: https://t.co/56rK1pflza #bcsm @OncoAlert
-
-
Mashup Score: 6FDA Approves First Targeted Therapy for HER2-Low Breast Cancer - 2 year(s) ago
FDA Approves First Targeted Therapy for HER2-Low Breast Cancer
Categories: Hem/Oncs, Latest HeadlinesTweet-
And day later: FDA approval of T-DxD, the first drug approved for HER2 low metastatic breast cancer. Time to rethink TNBC terminology - define tumors by what is present and actionable. #bcsm @OncoAlert Link: https://t.co/esIxtI7m2W https://t.co/pnbAfGQxUR
-
-
Mashup Score: 2FDA Approves First Targeted Therapy for HER2-Low Breast Cancer - 2 year(s) ago
FDA Approves First Targeted Therapy for HER2-Low Breast Cancer
Categories: Hem/Oncs, Latest HeadlinesTweet-
And a day later: FDA approval of T-DxD, the first drug approved for HER2 low metastatic breast cancer. Time to rethink TNBC terminology - define tumors by what it is present and actionable. Link: https://t.co/esIxtI7m2W https://t.co/pnbAfGQxUR
-
-
Mashup Score: 10
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Updated @ASCO guidelines: Pts with HER2 IHC 1 or 2+ (ISH neg), MBC, who have received 1 prior chemorx, endocrine-refractory ER+, should receive Trastuzumab Deruxtecan based on DB-04 results. @BeverlyMoy #bcsm @JCO_ASCO https://t.co/3ldTpKBgpO
-
@MPishvaian @ArielleMedford @TumorBoardTues @JohnEbbenMDPhD @elmayermd @AndreaMaliachi @maryam_lustberg @HeekeMd @DraAnaCasas @CarmenCalfa @atanmdlci @BoscoloLuca_ @DrRBarroso @Dr_R_Kurzrock @ElizSMcKenna @DrAmyComander @ValenzaCarmine @IBCradiation @matteolambe @antoniomarraMD @JAMouabbi @cancerdocsi @aftimosp @US_FDA @AdrianaKahnMD @malefitness @AZBioMarkers @katsuki_arima @patricia_stoop @GMaronge @HeatherMoore16 @NCCH_MD @ThanksCancer @ErikaHamilton9 @SABCSSanAntonio @teamoncology @raffcolo @gasingiltv @ESchattner @AMJohnston1315 @hmcarthur @Maimah @jesusanampa @KariWisinski_MD @stolaney1 Agree. Lot of interest in vaccines. Example: folate vaccine: https://t.co/ts5tlr3KZv